Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.

Pharmaceuticals (Basel) · 2025 · PMC12845451 · PMID 41599681

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with elevated baseline CRP (>ULN) and IL-6 (>LLOQ) showed a trend toward more pronounced treatment response—a finding potentially attributable to higher IL-6 activity and greater pathogenic significance of this cytokine in these patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.